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Abstract
Background: Malignant transformation of melanocytes is frequently attended by a switch in cadherin expression
profile as shown for E- and N-cadherin. For P-cadherin, downregulation in metastasizing melanoma has been
demonstrated, and over-expression of P-cadherin in melanoma cell lines has been shown to inhibit invasion. The
strong invasive and metastatic nature of cutaneous melanoma implies a deregulated interplay between
intercellular adhesion and migration-related molecules
Results: In this study we performed a microarray analysis to compare the mRNA expression profile of an invasive
BLM melanoma cell line (BLM LIE) and the non-invasive P-cadherin over-expression variant (BLM P-cad). Results
indicate that nonmuscle myosin II-B is downregulated in BLM P-cad. Moreover, myosin II-B plays a major role in
melanoma migration and invasiveness by retracting the tail during the migratory cycle, as shown by the
localization of myosin II-B stress fibers relative to Golgi and the higher levels of phosphorylated myosin light chain.
Analysis of P-cadherin and myosin II-B in nodular melanoma sections and in a panel of melanoma cell lines further
confirmed that there is an inverse relationship between both molecules.
Conclusions: Therefore, we conclude that P-cadherin counteracts the expression and function of myosin II-B,
resulting in the suppression of the invasive and migratory behaviour of BLM melanoma cells
Background
Cutaneous melanoma, an aggressive cancer type originat-
ing from melanocytes in the human skin, is characterized
as an invasive and commonly metastasizing tumor which
is the major cause of death of melanoma patients [1,2]
Normal cutaneous melanocytes form cell-cell contacts
with adjacent keratinocytes, providing a molecular anchor
by which melanocytes participate in the normal function
and architecture of the human skin. Malignant transfor-
mation of melanocytes is featured by downregulation of
cell-cell adhesion molecules like E- and P-cadherin, result-
ing in the loss of keratinocyte-mediated growth and moti-
lity control [3,4]. Concomitant with these changes,
melanoma cells often undergo a phenomenon, referred to
as epithelial-to-mesenchymal transition (EMT), and obtain
a migratory and protease-producing phenotype, leading to
invasion and the formation of distant metastasis [5,6].
P-cadherin is a calcium-dependent cell-cell adhesion
molecule belonging to the cadherin superfamily which
comprises transmembrane proteins grouped by the pre-
sence of one or more cadherin repeats in their extracellu-
lar domains. The classical cadherin family consists
of E(pithelial)-, N(euronal)-, V(ascular)E(ndothelial)- and
P(lacental)-cadherin, named after the tissue they were first
identified in [7,8]. Classical cadherins exert cohesive and
organising functions that are required for tissue develop-
ment and integrity. In contrast to the universal expression
of E-cadherin in epithelia, P-cadherin is only expressed in
the basal layer of squamous epithelia [9,10]. In epithelial-
derived cancer, cadherins are often downregulated result-
ing in decreased cellular cohesion, increased invasion and
formation of metastasis [11]. Our group showed that
stable introduction of P-cadherin in BLM melanoma cells
inhibits invasive capacities, stimulates homo- and hetero-
typic adhesion and induces an epithelioid phenotype [12].
Other experimental work elucidating the functions of
P-cadherin pointed out that this molecule can have an
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opposite role depending on the cellular context [9,12-14].
Non-muscle myosin II belongs to the myosin superfamily
and is an ATP-dependent molecular motor protein that
can interact with and contract filamentous actin (F-actin)
[15]. In vertebrates, three isoforms of the non-muscle
myosin II heavy chain have been described: II-A, II-B and
II-C. Each isoform is encoded by a specific gene and
despite considerable homology between the different iso-
forms, differences in subcellular localization, enzymatic
properties, filament assembly-disassembly regulation and
tissue expression patterns have been described [16]. Non-
muscle myosin II heavy chain B (myosin II-B) plays a
major role in the retraction phase of the migratory cycle in
contrast to the bipolar shape- and substrate adhesion-
related protrusion functions of nonmuscle myosin II heavy
chain A (myosin II-A) [17-19]. In migrating endothelial
cells, it has been shown that myosin II-A is more abun-
dant near the leading edge and myosin II-B in trailing
ends. Moreover, myosin II-A moves with a higher velocity
into new protrusions whereas myosin II-B is confined
much longer to the retraction site of the migrating cell
[20]. Myosin II-B filament assembly and ATPase activity
are regulated by phosphorylation via two main kinases,
myosin light chain kinase and Rho kinase, which phos-
phorylate Ser19 at the regulatory light chain [21-23].
We show here that the anti-migratory and anti-inva-
sive capacity of P-cadherin in BLM melanoma cells can
be related to P-cadherin-dependent downregulation and
organization of the myosin II-B isoform, implicating a
coordinated cross-talk between adhesion molecules and
cellular migration-related proteins.
Results
Myosin II-B is downregulated in BLM cells overexpressing
P-cadherin
Our group showed that stable introduction of P-cad-
herin in BLM melanoma cells induced major morpholo-
gical (epithelioid phenotype) and functional differences
(adhesion, invasion) between the two cell lines [12].
A microarray experiment performed with Affymetrix®
chips allowed us to detect transcriptional differences
between BLM LIE and BLM P-cad cells. Figure 1A
demonstrates that P-cadherin mRNA was strongly upre-
gulated in BLM P-cad in contrast to BLM LIE cells, as
expected, and that myosin II-B was downregulated in
BLM P-cad cells (GEO Accession Number GSE23360).
The results obtained from the microarray analysis were
confirmed by quantitative polymerase chain reaction
(qPCR). Normalised amounts of myosin II-B mRNA
were 12,39% versus 100% for BLM P-cad and BLM LIE,
respectively (figure 1B). Also on the protein level, down-
regulation of myosin II-B could be detected in BLM
P-cad (figure 1C). Furthermore, the presence of mem-
branous P-cadherin in BLM P-cad cells was validated
(figure 1D). Since myosin II-B belongs to the nonmuscle
myosin II family, which also contains closely-related
myosin II-A and II-C isoforms, we wanted to ensure
that myosin II-B was specifically downregulated in BLM
P-cad cells without an effect on II-A and II-C expres-
sion. Figure 1E shows that indeed myosin II-B was
specifically downregulated in BLM P-cad. We chose to
further investigate myosin II-B because of the statisti-
cally significant results of the microarray and qPCR data
and its contribution to cell migration as pointed out by
current scientific literature.
Myosin II-B co-localizes with F-actin bundles and
functions at the trailing end of migrating BLM cells
To provide information of myosin II-B filament assembly
and subcellular localization, we performed immunofluor-
escence staining of nonmuscle myosin II-B. Figure 2A
shows myosin II-B stress fiber formation in BLM LIE
cells in contrast to the faint and diffuse distribution of
myosin II-B in BLM P-cad cells. A double staining of
myosin II-B and F-actin shows co-localization of the
myosin stress fibers with F-actin bundles in BLM LIE
cells. Note that myosin II-B stress fiber formation is not
homogenous in BLM LIE cells, due to the fast and transi-
ent nature of myosin II function.
To determine whether myosin II-B stress fibers contri-
bute to tail retraction in melanoma cells, we performed a
double staining of myosin II-B and K58, a marker for the
Golgi apparatus. It has been shown that the position of
the Golgi and microtubule organizing centre faces the
leading edge of a migrating cell. Immunofluorescence
staining of the Golgi and myosin II-B therefore indicates
whether the observed myosin II-B stress fibers are formed
at the leading or trailing edge of the cell. Figure 2B shows
myosin stress fibers at the retraction site of polarized BLM
LIE cells.
Higher activation status of myosin II-B in BLM LIE than in
BLM P-cad
The activation status of nonmuscle myosin II can be
characterized by phosphorylation of the regulatory light
chain (MLC). This 20 kDa light chain contains two
main phosporylation sites; Ser19 and Thr18. Myosin
light chain kinase (MLCK) activity is necessary for the
monophosphorylation at Ser19 of myosin light chain,
thereby enhancing MgATPase activity and promoting
myosin II filamentation. We show here that a higher
level of total phosphorylated MLC can be detected in
BLM LIE cells compared with BLM P-cad cells. When
the phosphorylated MLC was precipitated, we stained
for myosin II-B in order to detect the amount of phos-
porylated MLC that was specifically bound to myosin
II-B. Figure 3 shows that low levels of activated
nonmuscle myosin II-B could be detected in the
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Figure 1 P-cadherin and myosin II-B expression in BLM LIE versus BLM P-cad. (A) Nonmuscle myosin heavy chain 10 (myosin II-B) mRNA
was downregulated in BLM P-cad cells according to microarray analysis. Cadherin 3 (P-cadherin) mRNA levels were, as expected, upregulated in
BLM P-cad. (B) Quantitative PCR validated the microarray data, indicating a 90% (± 5%) decrease in myosin II-B RNA expression in BLM P-cad
and no P-cadherin RNA levels in BLM LIE. Error bars show the standard deviation for 2 independent experiments. (C) Decreased myosin II-B
protein expression in BLM P-cad verifies microarray and PCR data. (D) Immunofluorescence staining of P-cadherin indicates the presence of
functional P-cadherin mediated cell-cell contacts in BLM P-cad. (E) Western blot of myosin II isoforms in BLM LIE and P-cad. Equal amounts
could be detected for myosin II-A, downregulation in BLM P-cad for myosin II-B, and no expression levels for myosin II-C. (scale bar = 25 μm)
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Figure 2 Confocal images of myosin II-B in BLM LIE and BLM P-cad. (A) Myosin II-B (red) confocal images with the F-actin cytoskeleton (green)
and merge with DAPI (blue) nuclear staining. The detailed images show the formation of myosin II-B stress fibers and colocalization with F-actin, as
indicated in the merge by yellow coloured stress fibers, in BLM LIE. Note the weak and diffuse myosin II-B staining pattern in BLM P-cad (scale bar =
50 μm, for detail image scale bar = 25 μm). (B) Immunofluorescence double staining of myosin II-B (red) and K58 Golgi protein (green). Position of
Golgi and myosin II-B relative to nucleus (blue) reveals the function of myosin II-B occurring at the trailing end (scale bar = 25 μm).
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non-invasive BLM P-cad cells in contrast to higher
levels in invasive BLM LIE cells.
Depletion of myosin II-B decreased cell migration and
invasion
Silencing of myosin II-B in BLM LIE cells resulted in
decreased wound healing migration; after 15 h, 72% (±
2,8%) of the wound was closed with BLM LIE control
cells whereas only 42% (± 1,4%) of the wound was
closed with BLM LIE cells silenced for myosin II-B. For
BLM P-cad cells, no significant difference could be
detected between control cells and cells silenced for
myosin II-B. Wound closure after 15 hours incubation
by BLM P-cad control cells and BLM P-cad siMyosin II-
B was 52% (± 5,6) and 47% (± 4,4), respectively. Regard-
ing to invasion, a significant reduction of invaded cells
through matrigel could be observed for BLM LIE
cells silenced for myosin II-B in contrast to BLM P-cad
cells (figure 4A and 4B).
Inhibiting MLCK activity reduces cellular migration
Since the main regulators of filament assembly and
ATPase activity of myosin II are myosin light chain
kinase (MLCK) and Rho kinase (Rock), we used specific
Figure 3 Western blot to verify molecularly the activation status of MLC associated with myosin II-B. The upper panel shows the levels of
phosphorylated MLC in BLM LIE and BLM P-cad cells in total lysate (TL) and purified by immunoprecipitation. BLM P-cad shows a reduced
amount of total phosphorylated MLC. Lower panels show the amount of phosphorylated MLC associated with myosin II-B by co-
immunoprecipitation, indicating the decreased activation status of myosin II-B.
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Figure 4 Function of myosin II-B in BLM melanoma cell migration and invasion. (A) Western blot to verify silencing of myosin II-B
expression 72 h post-transfection in BLM LIE and BLM P-cad cells. Matrigel invasion assay shows reduced invasion of BLM LIE siMyosin II-B when
compared to control cells (p < 0,0001). No significant difference could be observed for BLM P-cad siMyosin II-B compared to BLM P-cad
siControl (p = 0,2). (B) Reduced migration of BLM LIE siMyosin II-B compared to BLM LIE siControl could be observed (p = 0,008) (upper panel).
No significant difference between BLM P-cad siControl and siMyosin II-B could be detected (p = 0,7). Results of a wound healing assay with
addition of specific kinase inhibitors (lower panel). KT-5926 significantly reduced cellular migration when compared to control situation, in
contrast to Y27632 (p = 0,009; p = 0,98).
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inhibitors of MLCK (KT-5926) and Rock (Y-27632) to
identify which regulatory pathway is mainly involved in
the regulation of nonmuscle myosin II-regulated cellular
migration of BLM cells. By applying the wound healing
assay we found that in control situation, approximately
70% of the initial wound was closed. When cells were
incubated with Y27632 no significant difference in
wound closure could be detected. In contrast, after
treatment with KT-5926, approximately 45% of the
initial wound was closed (figure 4B).
An inverse relationship between P-cadherin and myosin
II-B expression in a panel of melanoma cell lines
Myosin II-B and P-cadherin expression levels were
determined in 11 melanoma cell lines thereby expanding
the hypothesis based on BLM cells to a wider panel of
melanoma cell lines. As shown in figure 5A, all mela-
noma cell lines, except MeWo, were negative for P-cad-
herin and staining for myosin II-B reveals a high
expression level in all melanoma cell lines.
Nodular melanoma sections showed cytoplasmic staining
for myosin II-B and an aberrant or absent P-cadherin
expression at the nodular tumor site
To support the hypothesis that P-cadherin-mediated cel-
lular cohesion and the expression and/or organisation of
myosin II-B inversely correlate in malignant melanoma
and contribute to invasion, we performed P-cadherin
and myosin II-B stainings on eight nodular melanoma
patient samples. Staining for P-cadherin showed a hon-
eycomb-like pattern in the normal epidermal layers. In
contrast, the tumor sites showed an aberrant or absent
P-cadherin expression, indicating diminished cellular
cohesion, which is an important aspect of invasion.
Alternately, stainings of adjacent section for myosin II-B
showed cytoplasmic staining in the tumor sites. Figure
5B presents two representative patient samples stained
for P-cadherin and myosin II-B.
Discussion
The formation of metastasis is the main cause of mor-
tality of cancer patients. These processes require an
initial, crucial step, namely invasion of tumor cells in
surrounding stroma, where loss of intercellular adhesion
and the gain of a migratory phenotype are of major
importance. Differentiating basal cells migrate perpendi-
cularly to the basal layer towards the surface of the skin,
and various established cell-cell contacts maintain the
epithelial structure and promote coordinated cellular
migration. However, melanoma has been described as a
strong invasive and metastasizing tumor, implicating
loss of cellular cohesion and simultaneously acquire-
ment of a migratory phenotype. Loss of cohesion has
been evidenced by showing a cadherin shift in
melanocytic tumors leading to decreased homo- and
heterotypical intercellular adhesion and providing mole-
cular anchors to interact with vascular endothelial cells
and fibroblasts [24,25]. The close relationship between
cell-cell adhesion proteins with polarity- and migration-
related proteins, both in normal tissue and tumor, impli-
cates a coordinated cross-talk between cell-cell adhesion
molecules and migration-related proteins. This interac-
tion has been shown between E-cadherin and polarity-
and migration-related proteins like Rho GTPases.
However, in most cases signal transduction pathways
are pointed out, in contrast to the functional effector
proteins [26,27]. In this paper, we describe that the
expression of P-cadherin counteracts the expression and
organization of nonmuscle myosin II-B which results in
the repression of the migratory and invasive behaviour
of melanoma cells. Due to the initial observation that
introduction of P-cadherin in invasive BLM melanoma
cells promoted cell-cell adhesion and counteracted inva-
sion [12], we tried to determine molecular targets of
P-cadherin that contribute to the anti-invasive and anti-
migratory effect mediated by P-cadherin. Nonmuscle
myosin II-B, implicated in cellular migration, cytokinesis
and other cellular activities, could be identified as a
functional effector protein that was downregulated in
BLM P-cad cells. Myosin II-B staining of BLM LIE and
BLM P-cad showed a stress fiber pattern in BLM LIE
occurring at the trailing end of a polarized migrating
cell, in contrast to BLM P-cad where no myosin II-B
stress fibers, but a faint and diffuse, cytoplasmic expres-
sion pattern could be detected. Moreover, the localiza-
tion of myosin II-B stress fibers relative to Golgi and
the function of myosin II-B in cellular migration and
invasion, demonstrates its contribution to these cellular
activities by retracting the tail. Furthermore, the amount
of phosphorylated regulatory light chain associated with
myosin II-B is significantly higher in BLM LIE than in
BLM P-cad. One of the morphological features of BLM
P-cad cells is the formation of lamellopodia and filopo-
dia but the tails of the cells are anchored by P-cadherin-
mediated cell-cell contacts. Since the subcellular locali-
zation of both P-cadherin and myosin II-B occur at the
same site of nucleus with reference to the Golgi appara-
tus, mutual and localized regulation can easily occur. All
the tested melanoma cell lines showed no P-cadherin
expression and high levels of myosin II-B. Interestingly,
MeWo has been described as a non-invasive melanoma
cell line and showed P-cadherin positivity. In order to
confirm whether the P-cadherin switch in accordance
with high myosin II-B expression effectively acts in mel-
anoma patients, we evaluated nodular melanomas for
P-cadherin and myosin II-B positivity, because of the
deep infiltrative nature of this melanoma subtype. Nor-
mal epidermal layers showed a strong honeycomb-like
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P-cadherin staining, designating the cohesive nature of
the normal skin. In contrast, the deeper tumor sites
showed an aberrant or lack of expression of P-cadherin.
Cross-talk between adhesion molecules, e.g. E-cad-
herin, N-cadherin and avb3 integrin, and melanoma
progression has been widely described. avb3 Integrin
expression in human melanomas promotes invasion
through physical interaction with MMP-2, and inducing
transendothelial migration by association with the
human neural cell adhesion molecule L1 expressed on
endothelium [28]. For cadherins, loss of E-cadherin
expression during melanoma progression has been
shown to promote melanoma migration and, paralleled
by N-cadherin upregulation, increased gap-junctional
and N-cadherin-mediated communication with dermal
fibroblasts and endothelial cells [29-31]. In this study,
we present an important effector molecule that can be
related to P-cadherin expression in invasive melanoma.
The molecular mechanism underlying P-cadherin-
mediated myosin II-B regulation concerning migration
and invasion will be the major focus for our future
research. Our data suggest that mainly MLCK activity
contributes to cellular migration in BLM melanoma
cells. This means in our proposed model that introduc-
tion of P-cadherin in melanoma cells results in spatial
MLCK inhibition at sites of P-cadherin-mediated cell-
cell contacts. Since melanocytes originate from segrega-
tion of cell lineages derived from the cephalic neural
crest, the neural genetic and epigenetic background may
not be overruled [32]. Therefore, we hypothesize that, as
shown in neuronal cells, cadherin expression can modu-
late calcium channels and thereby alter transient cal-
cium influxes and available intracellular calcium at sites
of cadherin-mediated cell-cell contacts, as several ion
channels and ion channel regulated proteins are pre-
sented in the microarray list (Additional file 1).
Figure 5 (A) Western blot to determine the relative amounts of P-cadherin and myosin II-B in a series of melanoma cell lines. High
expression levels of myosin II-B for all melanoma cell lines, and absent or low expression levels of P-cadherin could be detected. (B)
Immunohistochemical staining of myosin II-B and P-cadherin in nodular melanoma sections (NM). P-cadherin staining shows a honeycomb
pattern in normal epidermal layers in contrast to tumor sites. The faint and diffuse staining pattern of the tumor sites indicates loss of cellular
cohesion. Myosin II-B staining demonstrates strong positivity at tumor sites, whereas no staining could be observed in normal (epi)dermal layers.
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Directional migration of a neuron is the succession of
three major processes: protrusion of the leading edge,
cell body translocation and retraction of the trailing end
[33]. For each of these processes, a critical, regulating
role of calcium waves has been pointed out [34]. Impor-
tant, Shengyu Yang et al. recently showed that calcium-
influxes, rather than calcium release of intracellular
stores, are critical for growth-factor induced cell migra-
tion. Moreover, they describe that calcium channels
facilitating calcium-influxes activate MLCK specifically
at the trailing tail, without an effect on the phosphoryla-
tion status of myosin light chain at the lamellopodia,
supporting our hypothesis [35]. An intensively studied
calcium flux modulator is the NMDA receptor. Besides
its presence in an ‘industrial complex’ associated with
an enormous variety of cytoskeletal proteins (including
myosin II-B), cellular adhesion proteins (including cad-
herins) and signaling proteins (including calmodulin
kinase and tyrosine kinases) at the postsynaptic mem-
brane for regulating calcium influx, it is a known regula-
tor of cellular migration. Indeed, it has been shown that
there is a positive correlation between the rate of cell
movement and the amplitude and frequency of calcium
fluctuations governed by NMDA receptors [36,37].
Therefore, it would be interesting to explore further the
molecular link between cadherins, calcium signaling and
myosin II activity and their implications in melanoma
progression.
Conclusions
In general, we can conclude that the inhibition of inva-
sion and impaired migration of melanoma cells can, at
least partially, be ascribed to a P-cadherin-mediated
decreased myosin II-B expression and impaired organi-
zation. This interplay between adhesion and migration
may be an important strategy of the melanoma cell to
invade the deeper stroma and to form metastasis.
Methods
Plasmids, cDNA construction, retroviral transduction and
cell sorting
Plasmid and cDNA construction, retroviral transduction
and cell sorting of BLM melanoma cells containing
pLZRS-IRES-EGFP (BLM LIE) and pP-cadherin-IRES-
EGFP (BLM P-cad) were obtained as described earlier
[12].
Human cell lines and culture conditions
Parental BLM melanoma cells were obtained from
L. Van Kempen (University of Nijmegen, The Nether-
lands). Cells were grown and maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco BRL, Bel-
gium) containing 10% heat-inactivated fetal bovine
serum (Greiner Bio-One, Belgium), 100 IU per mL
penicillin, 100 μg per mL streptomycin and 2,5 μg per
mL amphotericin B. Other melanoma cell lines used
include SK-23, A-375, FM3P, FM45, FM87, MJM, FM3
D, MeWo, G361 and HMB-2. SK-23, A-375, MJM,
MeWo and HMB2 were maintained in DMEM (Gibco
BRL, Belgium) containing 10% heat-inactivated fetal
bovine serum (Greiner Bio-One, Belgium), and antibio-
tics. FM3P, FM3 D, FM45 and FM87 were maintained
in Roswell Park Memorial Institute 1640 (RPMI 1640)
(Gibco BRL, Belgium) and G361 cells were maintained
in McCoy’s 5A medium (Gibco BRL, Belgium).
Antibodies
Rabbit polyclonal anti-nonmuscle myosin II-A, B and C
(Cell Signaling Technology, MA, US) for Western blot
and immunoprecipitation experiments, rabbit polyclonal
anti-nonmuscle myosin II-B (Covance, CA, US) for
immunofluorescence and immunohistochemistry, mouse
monoclonal anti-58K Golgi protein (Abcam, UK), rabbit
polyclonal anti-phospho-myosin light chain (pSer19)
(Sigma, MO, US), monoclonal mouse anti-P-cadherin
clone 56 (BD Biosciences, Belgium). Anti-a-tubulin anti-
body (Sigma, MO, US) was used as loading control for
Western blot. Secondary antibodies used for Western
blot were ECL™ anti-mouse IgG horseradish peroxidase
linked whole antibody from sheep and ECL™ anti-rabbit
IgG horseradish peroxidase linked whole antibody from
donkey (GE Healthcare, UK). For immunostaining,
Alexa Fluor 594 goat anti-mouse and anti-rabbit IgG
and Alexa Fluor 488 goat anti-rabbit and anti-mouse
IgG (Invitrogen, Belgium) were applied.
Polyacrylamide gel electrophoresis (PAGE), Western
blotting and immunoprecipitation experiments
Cells were lysed using PBS containing 1% Triton X-100,
1% NP40 (Sigma, MO, US) and the following protease
inhibitors: Leupeptin (10 μg/mL), aprotinin (10 μg/mL)
(ICN Biomedicals, CA, US), phenylmethylsulfonyl fluoride
(1.72 mM), NaF (100 μM), NaVO3 (500 μM), and
Na4P2O7 (500 μg/mL) (Sigma, MO, US). After preparing
lysates, protein concentration was measured using Rc-Dc
protein assay kit (Bio-Rad Laboratories S.A.-N.V,
Belgium). For immunoprecipitation experiments, primary
antibody was added to the supernatant and incubated for
3 h at 4° C followed by the addition of protein A- or G
Sepharose (Amersham Pharmacia Biotech, UK) beads for
1 hour. Sample buffer (Laemmli) was added, sample was
boiled and proteins were separated by electrophoresis and
blotted onto a nitrocellulose membrane (Amersham Phar-
macia Biotech, UK) and immunostained in PBS supple-
mented with 0,5% tween 20 (Duchefa Biochemie, The
Netherlands) and 5% non-fat dry milk in PBS. Chemilumi-
nescent substrate (ECL Western blotting detection
reagent, GE Healthcare, Belgium) was added and a film
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was exposed. Films were scanned (Epson perfection 4990,
Epson, Belgium) and bands were quantified using Quantity
One® software (Bio-Rad Laboratories S.A.-N.V, Belgium).
Confocal imaging of myosin II-B, F-actin and 58K Golgi
protein
For myosin II-B immunofluorescence staining, BLM
cells were fixed in 3,7% formaldehyde in Cytoskeleton
Stabilization Buffer (CSB) (NaCl (137 mM), KCl
(5 mM), NA2HPO4.2H20 (1,1 mM), KH2PO4
(0,4 mM), MgCl2.6H20 (2 mM), EGTA (2 mM), PIPES
(5 mM) and D-Glucose (5,5 mM) dissolved in desio-
nised water). Fixed cells were permeabilized with 0,5%
Triton X-100 (Bio-Rad Laboratories, Belgium) in CSB.
Cells were treated with 50 mM NH4Cl and blocked
with 5% albumin from bovine serum (Sigma, MO, US).
Afterwards, primary antibody was applied for 1 hour on
room temperature and the secondary antibody for
30 minutes. For F-actin/myosin II-B double staining, a
mixture of 15 μL phalloidin-fluorescein isothiocyanate
(20 mM) (Sigma, MO, US), 585 μL phosphate-buffered
saline, 3 μL MgSO4 (1 M) and 30 μL ethylene glycol
tetraacetic acid (0,1 M) was combined with the anti-
rabbit secondary antibody.
RNA isolation, microarray analysis and quantitative PCR
RNA isolation was performed using an RNeasy mini-kit
(Qiagen Benelux, The Netherlands) according to manufac-
turer’s instructions. RNA concentration and purity were
determined spectrophotometrically using the Nanodrop
ND-1000 (Nanodrop Technolgies, DE, US) and RNA
integrity was assessed using a Bioanalyser 2100 (Agilent,
CA, US). Per sample, an amount of 2 μg of total RNA
spiked with bacterial RNA transcript positive controls
(Affymetrix, UK) was converted and amplified to double
stranded cDNA in a 1-cycle cDNA reverse transcription
reaction. Subsequently the sample was converted to anti-
sense cRNA and labeled with biotin through an in vitro
transcription reaction according to the manufacturers pro-
tocol (Affymetrix, UK). All amplification and labelling
reactions were performed on a Biomek 3000 ArrayPlex
Workstation (Beckman Coulter, Belgium). A mixture of
purified and fragmented biotinylated cRNA and hybridisa-
tion controls (Affymetrix, UK) was hybridised on Affyme-
trix HG U133 Plus 2.0 arrays followed by staining and
washing in the GeneChip® fluidics station 400 (Affymetrix,
UK) according to the manufacturer’s procedures. To
assess the raw probe signal intensities, chips were scanned
using the GeneChip® scanner 3000 (Affymetrix, UK).
Probe signal intensities were statistically analyzed by Stu-
dent t-test and statistically significant results were checked
by quantitative polymerase chain reaction (qPCR) using
SYBR green method as described by M. Van Gele [38]. To
quantify the gene expression levels of nonmuscle myosin
II heavy chain B (MYH10) and P-cadherin (CDH3) tran-
scripts, primer sequences were designed using Primer
Express software (Applied Biosystems, CA, US) (MYH10
forward primer: CCTCATGCTGACCTTGCAAA -
reverse primer: GGACACAAAACCAATATTCCCATT)
(CDH3 forward primer: AGTGGAGGACCCCATGAACA
- reverse primer: CTGGGTAAACTTGGGCTTGTG) A
BLAST search was used to assure that these primers were
specific for nonmuscle myosin II heavy chain B and P-cad-
herin. Relative gene expression levels were determined
using a SYBR Green I reverse transcription-PCR assay as
described by Vandesompele et al. and the comparative Ct
method was used for quantification [39,40].
Transfection of short interference RNA
Sense and antisense short interference RNA (siRNA) oli-
gos for myosin II-B [RefSeq NM_005964, Swiss-Prot:
P35580] silencing were synthesized by Sigma (St. Louis,
MO, US). As negative control siRNA against firefly luci-
ferase was used. Transfection of siRNA was performed
by electroporation using Amaxa Nucleofector™ accord-
ing to manufacturer’s protocol. Functional assays were
performed 72 h after transfection.
Wound healing assay
For the analysis of directional migration, we made use of
the wound healing assay. For the myosin II-B silencing
experiments, cells were collected and electroporated as
described above. After electroporation, 300’000 cells
were seeded onto 6-well plate. After 72 hours a wound
was made in the monolayer and every 3 hours until
15 hours after wounding, a picture was made. After the
experiment, the diameter of the initial wound was mea-
sured and relative wound closure based on initial wound
diameter, was calculated. Three independent experi-
ments were performed and a Student t-test (a = 0,05)
was used for statistical significance. For wound healing
assay using pharmacological modulators Y27632 and
KT5926, inhibiting Rho kinase activity and an inhibitor
of myosin light chain kinase (MLCK) activity, respec-
tively, cells were seeded onto 6-well plate and incubated
for 72 hours until desired confluency was reached.
Then, medium containing 2 μM KT5926 or 10 μM
Y27632 and controls were added to the wells. Plates
were incubated for one hour and a wound was
scratched. Further steps were similar as described above.
Matrigel invasion assay
To test invasion through extracellular matrix, we made
use of the Matrigel invasion assay. Briefly, transwell
chambers with polycarbonate membrane filters (8.0 μm
pore size, 6.5 mm diameter, Costar, NY, US) were
coated with 40 μL of matrigel solution (Becton Dickin-
son). BLM melanoma cells were added on top of the
Jacobs et al. Molecular Cancer 2010, 9:255
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matrigel solution 60 hours post transfection. Condi-
tioned medium of cultured CT5.3 myofibroblasts was
added as a chemoattractant in the lower compartment.
After 24 hours incubation, the remaining (invasive) cells
at the lower surface of the filter were fixed with cold
methanol and stained with 4’,6’-diamidino-2-phenylin-
dole (DAPI) (Sigma-Aldrich, Belgium). Invasive cells
were scored by counting 30 fields per filter with a fluor-
escence microscope, at × 200 of magnification. Statisti-
cal significance was determined by the Student’s t-test;
p < 0.05 was considered significant.
Immunohistochemical staining
5 μ thick paraffin slides of eight nodular melanomas
were cut and pretreated with protease-1 (Ventana,
France) for four minutes. Indirect immunohistochemical
staining was performed with polyclonal antibodies direc-
ted against myosin II-B and P-cadherin for 30 minutes
according to the manufacturer’s protocol (Ventana,
France) and by use of the automated Benchmark®
system (Ventana, France).
Additional material
Additional file 1: Downregulated calcium channels and associated
proteins in BLM P-cad as indicated in the microarray experiment.
Overview of mRNA sequences that were considered to be
downregulated in the microarray experiment concerning calcium
signaling. The right column shows the identification of the probe set
that was used during the microarray experiment. The gene title reflects
the gene name that corresponds to the sequence that was differentially
detected in both cell lines. The ratio(2logX) shows the numeric detection
difference of a mRNA sequence between BLM LIE and BLM P-cad. Minus
indicates a downregulation in BLM P-cad and the factor is of logarithmic
scale.
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